ATE120757T1 - Diagnostischer test für plasminogenaktivatoren vom gewebs- und urokinasetyp und dafür kodierende gene. - Google Patents

Diagnostischer test für plasminogenaktivatoren vom gewebs- und urokinasetyp und dafür kodierende gene.

Info

Publication number
ATE120757T1
ATE120757T1 AT87905549T AT87905549T ATE120757T1 AT E120757 T1 ATE120757 T1 AT E120757T1 AT 87905549 T AT87905549 T AT 87905549T AT 87905549 T AT87905549 T AT 87905549T AT E120757 T1 ATE120757 T1 AT E120757T1
Authority
AT
Austria
Prior art keywords
activationers
tissue
diagnostic test
genes coding
type plasminogen
Prior art date
Application number
AT87905549T
Other languages
English (en)
Inventor
David J Loskutoff
Tor Ny
Michael Sawdey
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25408764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE120757(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Application granted granted Critical
Publication of ATE120757T1 publication Critical patent/ATE120757T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8132—Plasminogen activator inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9726—Tissue plasminogen activator

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AT87905549T 1986-08-19 1987-08-19 Diagnostischer test für plasminogenaktivatoren vom gewebs- und urokinasetyp und dafür kodierende gene. ATE120757T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/897,990 US4952512A (en) 1984-06-22 1986-08-19 Gene encoding an inhibitor of tissue-type and urokinase-type plasminogen activators

Publications (1)

Publication Number Publication Date
ATE120757T1 true ATE120757T1 (de) 1995-04-15

Family

ID=25408764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87905549T ATE120757T1 (de) 1986-08-19 1987-08-19 Diagnostischer test für plasminogenaktivatoren vom gewebs- und urokinasetyp und dafür kodierende gene.

Country Status (10)

Country Link
US (1) US4952512A (de)
EP (1) EP0277212B1 (de)
JP (2) JP2619452B2 (de)
KR (1) KR960005735B1 (de)
AT (1) ATE120757T1 (de)
AU (1) AU611095B2 (de)
DE (1) DE3751224T2 (de)
DK (1) DK175519B1 (de)
NO (1) NO302477B1 (de)
WO (1) WO1988001273A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422090A (en) * 1984-08-13 1995-06-06 Biotechnology Australia, Pty., Ltd. Human PAI-2
US5871956A (en) * 1984-12-06 1999-02-16 Amgen Inc. Recombinant methods for production of serine inhibitors and DNA sequences useful for same
US6291662B1 (en) 1984-12-05 2001-09-18 Amgen Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences
US6132990A (en) * 1984-12-06 2000-10-17 Amgen Boulder Inc. Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
US5900400A (en) * 1984-12-06 1999-05-04 Amgen Inc. Serine protease inhibitor analogs
US5853978A (en) * 1985-12-04 1998-12-29 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use
US6534285B1 (en) 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US6271352B1 (en) 1985-07-12 2001-08-07 Fonden Til Fremme Af Eksperimentel Cancerforskning PAI-1 determination and use thereof
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
SE8802939D0 (sv) * 1988-08-19 1988-08-19 Kabigen Ab A method for the production and isolation of a fusion protein in eukaryotic cells
AU5649390A (en) * 1989-05-11 1990-11-29 E.I. Du Pont De Nemours And Company High level expression of functional human plasminogen activator inhibitor (PAI-1) in E. Coli
WO1991002057A1 (en) * 1989-08-09 1991-02-21 Delta Biotechnology Limited Polypeptide production in fungi
US5260419A (en) * 1991-03-20 1993-11-09 The Dupont Merck Pharmaceutical Company Purification of active and inactive/latent forms of plasminogen activator inhibitor-1
US6869925B1 (en) 1992-09-09 2005-03-22 Amgen Inc. Inhibition of retrovirus infection
US5474766A (en) * 1992-12-18 1995-12-12 Washington University Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
US5550213A (en) * 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
US6017880A (en) * 1994-03-09 2000-01-25 Amgen Inc. Inhibition of retrovirus infection
US5639726A (en) * 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
BRPI9715293B1 (pt) * 1996-06-26 2016-11-01 Osram Ag elemento de cobertura para um elemento de construção optoeletrônico
US6600908B1 (en) 1999-02-04 2003-07-29 Hark C. Chan Method and system for broadcasting and receiving audio information and associated audio indexes
DK1887359T3 (da) * 2006-08-03 2009-03-02 Cellzome Ag Fremgangsmåde til identifikation af PI3K-interagerende molekyler og til rensning af PI3K
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235960A (en) * 1977-07-29 1980-11-25 The Medical College Of Wisconsin, Inc. Competitive enzyme-linked immunoassay
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4791068A (en) * 1984-06-22 1988-12-13 Scripps Clinic And Research Foundation Diagnostic assay for inhibitor of tissue-type and urokinase-type plasminogen activators
DK319685A (da) * 1985-07-12 1987-01-13 Fonden Til Fremme Af Eksperime Monoklonale antistoffer, fremgangsmaade til frembringelse af antistofferne, hybridomaceller, der producerer antistofferne, og anvendelse af antistofferne
NL8602307A (nl) * 1986-09-12 1988-04-05 Stichting Centraal Lab Recombinant dna molekuul; werkwijze voor het bereiden van humane endotheliale plasminogeen activator remmer (pai) of een mutant daarvan; farmaceutisch preparaat; getransformeerde gastheercellen.
DE3713272A1 (de) * 1987-04-18 1988-11-03 Behringwerke Ag Plasminogenaktivator-inhibitor, typ 2 (pai-2)

Also Published As

Publication number Publication date
WO1988001273A1 (en) 1988-02-25
EP0277212A1 (de) 1988-08-10
AU611095B2 (en) 1991-06-06
KR880701728A (ko) 1988-11-04
DK210788A (da) 1988-06-20
JP2685742B2 (ja) 1997-12-03
NO881670L (no) 1988-06-17
KR960005735B1 (ko) 1996-05-01
NO302477B1 (no) 1998-03-09
DK175519B1 (da) 2004-11-22
DE3751224D1 (de) 1995-05-11
DE3751224T2 (de) 1995-11-09
NO881670D0 (no) 1988-04-18
EP0277212B1 (de) 1995-04-05
DK210788D0 (da) 1988-04-18
JPH09131192A (ja) 1997-05-20
JPH01500640A (ja) 1989-03-09
JP2619452B2 (ja) 1997-06-11
AU7851487A (en) 1988-03-08
US4952512A (en) 1990-08-28
EP0277212A4 (en) 1991-04-10

Similar Documents

Publication Publication Date Title
ATE120757T1 (de) Diagnostischer test für plasminogenaktivatoren vom gewebs- und urokinasetyp und dafür kodierende gene.
Kristensen et al. Human endothelial cells contain one type of plasminogen activator
Levin et al. Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells.
Eaton et al. Phorbol ester and mitogens stimulate human fibroblast secretions of plasmin-activatable plasminogen activator and protease nexin, an antiactivator/antiplasmin.
Hekman et al. Fibrinolytic pathways and the endothelium
Shafer et al. Human lysosomal cathepsin G and granzyme B share a functionally conserved broad spectrum antibacterial peptide.
DE69123981T3 (de) Nützliche retrovirale vektoren für die gentherapie
MY102472A (en) Preparation of funtional human urokinase proteins.
SE8801701D0 (sv) Production technology based on enzymic method
ES8607262A1 (es) Esteres de aminoacidos y de peptidos cromogenos
Parcq et al. Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain
Brezniak et al. Human. alpha.-to. zeta.-thrombin cleavage occurs with neutrophil cathepsin G or chymotrypsin while fibrinogen clotting activity is retained
GB1533205A (en) Plasmin fractions and complexes thereof
DE69432608D1 (de) Expression von inhibitoren vom plasminogenaktivator vom urokinasetyp
DE3688324D1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
Siebenlist et al. Evidence for Intramolecular Cross-Linked Aα⊙ γ Chain Heterodimers in Plasma Fibrinogen
Stephens et al. Novel properties of human monocyte plasminogen activator
Leung et al. The resistance of fibrin-stimulated tissue plasminogen activator to inactivation by a class PAI-2 inhibitor (minactivin)
de Petro et al. Tissue type plasminogen activator, but not urokinase, exerts transformation‐enhancing activity
FR2723097B1 (fr) Thioredoxines h de ble tendre et de ble dur et proteines presentant des similitudes, fragments d'adncodant pour ces proteines et procedes d'obtention
DE60044038D1 (de) Xylosyltransferase und isoformen
DE69332373D1 (de) Menschlicher epidermaler Gen-Promotor
ATE120491T1 (de) Ausgeglichenes, konstitutives, induzierbares transkriptionssystem.
Larsson et al. Properties of the complex between α2-macroglobulin and brinase, a proteinase from aspergillus oryzae with thrombolytic effect
Pierard et al. MUTANT AND CHIMAERIC RECOMBINANT PLASMINOGEN ACTIVATORS

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time